LYEL
insider transactionsLyell Immunopharma, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 90d
-2.8K
0 buy · 2.8K sell
Net value · 90d
-$40.6K
$0 in · $40.6K out
Sentiment · 90d
Net selling
0% buying · 100% selling
Open-market trades · 90d
5
0 buy · 2.8K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Other·J
$0
66.5K sh
-
Sell·S
Chief Medical Officer
$25.0K
2.0K sh · $12.64
Own -9%
-
Grant·A
Director
$0
9.2K sh
Own New
-
Grant·A
Director
$0
9.2K sh
Own New
-
Grant·A
Director
$0
9.2K sh
Own New
-
Grant·A
Director
$0
9.2K sh
Own New
-
Grant·A
Director
$0
9.2K sh
Own New
-
Sell·S
Lynn Seely KEY
President and CEO
$7.3K
388 sh · $18.91
Own -1%
-
Sell·S
Chief Scientific Officer
$2.5K
130 sh · $18.92
Own -1%
-
Sell·S
Chief Operating Officer
$1.7K
89 sh · $18.92
Own -0%
-
Sell·S
VP, Corporate Controller
$4.1K
217 sh · $18.91
Own -1%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 15, 2026 | Innovative Cellular Therapeutics Holdings Ltd | Other J | 66.5K | $0 |
| Jun 10, 2026 | David Shook | Sell S | 2.0K | $25.0K |
| Jun 10, 2026 | Elizabeth G Nabel | Grant A | 9.2K | $0 |
| Jun 10, 2026 | Sumant Ramachandra | Grant A | 9.2K | $0 |
| Jun 10, 2026 | William Jl Rieflin | Grant A | 9.2K | $0 |
| Jun 10, 2026 | Cathy Friedman | Grant A | 9.2K | $0 |
| Jun 10, 2026 | Mark Bachleda | Grant A | 9.2K | $0 |
| May 11, 2026 | Lynn Seely KEY | Sell S | 388 | $7.3K |
| May 11, 2026 | Gary K. Lee | Sell S | 130 | $2.5K |
| May 11, 2026 | Stephen J. Hill | Sell S | 89 | $1.7K |
| May 11, 2026 | Veronica Sanchez Bulis | Sell S | 217 | $4.1K |
About LYEL insider trading
This page tracks insider transactions for Lyell Immunopharma, Inc. (LYEL) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.